ACRIS COMBI

This brand name is authorized in Australia.

Active ingredients

The drug ACRIS COMBI contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII OFG5EXG60L - RISEDRONATE SODIUM
 

Risedronic acid is a pyridinyl bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. The bone turnover is reduced while the osteoblast activity and bone mineralisation is preserved.
 
Read more about Risedronic acid
2
UNII H0G9379FGK - CALCIUM CARBONATE
 

Calcium carbonate releases, in a pH-dependent manner, calcium ions in the stomach. Calcium carbonate is widely used as antacid and extensively used as a dietary supplement.
 
Read more about Calcium carbonate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
M05BB02 Risedronic acid and calcium, sequential M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BB Bisphosphonates, combinations
Discover more medicines within M05BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 4059P, 8899J

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈